Not provided
Not provided
Not provided
Not provided
Not provided
REAL trial showed a significant difference in OS for reduced EOX and standard EOX
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Amgen | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| treatment | Experimental | 3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Epirubicine, Oxaliplatin, Capecitabine, Panitumumab | Drug | 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21 |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy | Proportion of patients with T0 ant T1 disease after neoadjuvant combined chemoimmunotherapy | |
| Safety | Proportion of patients with grade 4 diarrhea |
| Measure | Description | Time Frame |
|---|---|---|
| Histopathological response | rate of complete pathological response | |
| overall survival after one year | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| LKH Feldkirch | Feldkirch | 6807 | Austria | |||
| KH Elisabethinen Linz |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Progression free survival after one year |
| Proportion of patients completing 3 treatment cycles |
| Safety | NCI CTCAE v.3 |
| Linz |
| 4010 |
| Austria |
| AKh Linz | Linz | 4021 | Austria |
| Universitätsklinik für Innere Medizin III | Salzburg | 5020 | Austria |
| Klinikum Kreuzschwestern Wels GmbH | Wels | 4600 | Austria |
| St. Vinzenz Krankenhaus Betriebs GmbH | Zams | 6511 | Austria |
| ID | Term |
|---|---|
| D015251 | Epirubicin |
| D000077150 | Oxaliplatin |
| D000069287 | Capecitabine |
| D000077544 | Panitumumab |
| ID | Term |
|---|---|
| D004317 | Doxorubicin |
| D003630 | Daunorubicin |
| D018943 | Anthracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D056831 | Coordination Complexes |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D005472 | Fluorouracil |
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided